13 analysts have expressed a variety of opinions on ACADIA Pharmaceuticals ACAD over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 5 | 4 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 3 | 4 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $28.46, a high estimate of $37.00, and a low estimate of $19.00. A decline of 3.13% from the prior average price target is evident in the current average.
Analyzing Analyst Ratings: A Detailed Breakdown
A comprehensive examination of how financial experts perceive ACADIA Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Gregory Renza | RBC Capital | Maintains | Outperform | $29.00 | $29.00 |
| Tazeen Ahmad | B of A Securities | Lowers | Neutral | $22.00 | $26.00 |
| Ami Fadia | Needham | Maintains | Buy | $30.00 | $30.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $37.00 | $37.00 |
| Andrew Fein | HC Wainwright & Co. | Lowers | Buy | $27.00 | $33.00 |
| David Hoang | Citigroup | Lowers | Buy | $30.00 | $30.19 |
| Paul Matteis | Stifel | Lowers | Hold | $21.00 | $26.00 |
| Uy Ear | Mizuho | Lowers | Neutral | $21.00 | $25.00 |
| Joel Beatty | Baird | Lowers | Outperform | $28.00 | $31.00 |
| Jay Olson | Oppenheimer | Maintains | Perform | $19.00 | $19.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $37.00 | $37.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $37.00 | - |
| Ami Fadia | Needham | Maintains | Buy | $32.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ACADIA Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of ACADIA Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ACADIA Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on ACADIA Pharmaceuticals analyst ratings.
Delving into ACADIA Pharmaceuticals's Background
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Understanding the Numbers: ACADIA Pharmaceuticals's Finances
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: ACADIA Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 73.75%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: ACADIA Pharmaceuticals's net margin excels beyond industry benchmarks, reaching 8.04%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): ACADIA Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.7% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): ACADIA Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.06%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.13, ACADIA Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Core of Analyst Ratings: What Every Investor Should Know
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
